nach oben

International Journal of Clinical Oncology

Erschienen in:

17.06.2022 | Original Article

Characteristics and clinical outcomes of patients with advanced gastric or gastroesophageal cancer treated in and out of randomized clinical trials of first-line immune checkpoint inhibitors

verfasst von: Yu Aoki, Akihito Kawazoe, Yohei Kubota, Keigo Chida, Saori Mishima, Daisuke Kotani, Yoshiaki Nakamura, Yasutoshi Kuboki, Hideaki Bando, Takashi Kojima, Toshihiko Doi, Takayuki Yoshino, Takeshi Kuwata, Kohei Shitara

Erschienen in: International Journal of Clinical Oncology | Ausgabe 9/2022

Einloggen, um Zugang zu erhalten

Abstract

Background

Although several randomized trials (RCTs) showed survival benefits of immune checkpoint inhibitor (ICI) plus first-line chemotherapy for advanced gastric or gastroesophageal cancer (AGC), these trials could enroll patients who fulfilled the strict eligibility criteria or waited for certain screening period for central assessment of PD-L1 status.

Methods

We retrospectively compared characteristics and clinical outcomes of the patients with AGC who received first-line chemotherapy in control arm of RCTs with ICIs (control group) or clinical practice (practice group) at our institution from February 2016 to April 2019.

Results

The control group had a better baseline Eastern Cooperative Oncology Group performance status (PS0, 81.2% vs. 51.4%, p < 0.001) and a longer interval from first visit to first-line chemotherapy initiation (19 days vs. 9 days, p < 0.001) than the practice group. Median overall survival (OS) was 20.3 months in control group and 15.7 months in practice group, with a trend of longer OS in control group than that in practice group (hazard ratio, 0.71; p = 0.062). More patients in control group were treated with subsequent chemotherapy including ICIs.

Conclusion

Patients with AGC in RCTs of ICIs had a better PS or a higher chance to receive subsequent chemotherapy, resulting in a better prognosis than those treated in clinical practice. This information should be considered when interpreting RCT results and applying new treatments into clinical practice.

Nur mit Berechtigung zugänglich

Han JJ, Kim JW, Suh KJ et al (2019) Clinical characteristics and outcomes of patients enrolled in clinical trials compared with those of patients outside clinical trials in advanced gastric cancer. Asia Pac J Clin Oncol 15:158–165. https://doi.org/10.1111/ajco.13145CrossRefPubMed

Unger JM, Barlow WE, Martin DP, et al (2014) Comparison of survival outcomes among cancer patients treated in and out of clinical trials. Jnci J National Cancer Inst 106:dju002. https://doi.org/10.1093/jnci/dju002

Go RS, Frisby KA, Lee JA et al (2006) Clinical trial accrual among new cancer patients at a community-based cancer center. Cancer 106:426–433. https://doi.org/10.1002/cncr.21597CrossRefPubMed

Elting LS, Cooksley C, Bekele BN et al (2006) Generalizability of cancer clinical trial results. Cancer 106:2452–2458. https://doi.org/10.1002/cncr.21907CrossRefPubMed

Ohno S, Mukai H, Narui K et al (2019) Participants in a randomized controlled trial had longer overall survival than non-participants: a prospective cohort study. Breast Cancer Res Treat 176:631–635. https://doi.org/10.1007/s10549-019-05276-yCrossRefPubMed

Braunholtz DA, Edwards SJL, Lilford RJ (2001) Are randomized clinical trials good for us (in the short term)? Evidence for a “trial effect.” J Clin Epidemiol 54:217–224. https://doi.org/10.1016/s0895-4356(00)00305-xCrossRefPubMed

Peppercorn JM, Weeks JC, Cook EF et al (2004) Comparison of outcomes in cancer patients treated within and outside clinical trials: conceptual framework and structured review. Lancet 363:263–270. https://doi.org/10.1016/s0140-6736(03)15383-4CrossRefPubMed

Janjigian YY, Shitara K, Moehler M et al (2021) First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 398:27–40. https://doi.org/10.1016/s0140-6736(21)00797-2CrossRefPubMedPubMedCentral

Shitara K, Cutsem EV, Bang Y-J et al (2020) efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer. Jama Oncol 6:1571–1580. https://doi.org/10.1001/jamaoncol.2020.3370CrossRefPubMed

10.

Kubota Y, Kawazoe A, Sasaki A et al (2020) The impact of molecular subtype on efficacy of chemotherapy and checkpoint inhibition in advanced gastric cancer. Clin Cancer Res 26:3784–3790. https://doi.org/10.1158/1078-0432.ccr-20-0075CrossRefPubMed

11.

Fuchs CS, Muro K, Tomasek J et al (2017) prognostic factor analysis of overall survival in gastric cancer from two phase iii studies of second-line ramucirumab (REGARD and RAINBOW) using pooled patient data. J Gastric Cancer 17:132–144. https://doi.org/10.5230/jgc.2017.17.e16CrossRefPubMedPubMedCentral

12.

Takahari D, Boku N, Mizusawa J et al (2014) Determination of prognostic factors in japanese patients with advanced gastric cancer using the data from a randomized controlled trial, Japan clinical oncology group 9912. Oncologist 19:358–366. https://doi.org/10.1634/theoncologist.2013-0306CrossRefPubMedPubMedCentral

13.

Kang Y-K, Chen L-T, Ryu M-H et al (2022) Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 23:234–247. https://doi.org/10.1016/s1470-2045(21)00692-6CrossRefPubMed

14.

Kang Y-K, Boku N, Satoh T et al (2017) Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390:2461–2471. https://doi.org/10.1016/s0140-6736(17)31827-5CrossRefPubMed

15.

Catenacci DVT, Kang Y-K, Saeed A et al (2021) FIGHT: A randomized, double-blind, placebo-controlled, phase II study of bemarituzumab (bema) combined with modified FOLFOX6 in 1L FGFR2b+ advanced gastric/gastroesophageal junction adenocarcinoma (GC). J Clin Oncol. https://doi.org/10.1200/jco.2021.39.15_suppl.4010CrossRef

16.

Nakamura Y, Taniguchi H, Ikeda M et al (2020) Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies. Nat Med 26:1859–1864. https://doi.org/10.1038/s41591-020-1063-5CrossRefPubMed

17.

Kather JN, Pearson AT, Halama N et al (2019) Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer. Nat Med 25:1054–1056. https://doi.org/10.1038/s41591-019-0462-yCrossRefPubMedPubMedCentral

18.

Yamashita R, Long J, Longacre T, et al Deep learning model for the prediction of microsatellite instability in colorectal cancer: a diagnostic study. The Lancet Oncology 22: 132–141.

Titel: Characteristics and clinical outcomes of patients with advanced gastric or gastroesophageal cancer treated in and out of randomized clinical trials of first-line immune checkpoint inhibitors
verfasst von: Yu Aoki
Akihito Kawazoe
Yohei Kubota
Keigo Chida
Saori Mishima
Daisuke Kotani
Yoshiaki Nakamura
Yasutoshi Kuboki
Hideaki Bando
Takashi Kojima
Toshihiko Doi
Takayuki Yoshino
Takeshi Kuwata
Kohei Shitara
Publikationsdatum: 17.06.2022
Verlag: Springer Nature Singapore
Erschienen in: International Journal of Clinical Oncology / Ausgabe 9/2022
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-022-02200-1

Springer Medizin

Characteristics and clinical outcomes of patients with advanced gastric or gastroesophageal cancer treated in and out of randomized clinical trials of first-line immune checkpoint inhibitors